Pharmacologic Hedgehog inhibition modulates the cytokine profile of osteolytic breast cancer cells.

ABSTRACT: The establishment and progression of bone metastatic breast cancer is supported by immunosuppressive myeloid populations that enable tumor growth by dampening the innate and adaptive immune response. Much work remains to understand how to target these tumor-myeloid interactions to improve treatment outcomes. Noncanonical Hedgehog signaling is an essential component of bone metastatic tumor progression, and prior literature suggests a potential role for Hedgehog signaling and its downstream effector Gli2 in modulating immune responses. In this work, we sought to identify if inhibition of noncanonical Hedgehog signaling alters the cytokine profile of osteolytic breast cancer cells and the subsequent communication between the tumor cells and myeloid cells. Examination of large patient databas

SUBMITTER: Bennett NE 

PROVIDER: S-EPMC11342115 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature